Cogent Biosciences, Inc. (COGT)
| Market Cap | 5.20B +146.4% |
| Revenue (ttm) | n/a |
| Net Income | -407.68M |
| EPS | -2.48 |
| Shares Out | 174.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,606,732 |
| Open | 31.93 |
| Previous Close | 31.64 |
| Day's Range | 28.80 - 32.33 |
| 52-Week Range | 27.74 - 43.73 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 55.73 (+86.45%) |
| Earnings Date | Nov 5, 2026 |
About COGT
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a rev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price target is $55.73, which is an increase of 86.45% from the latest price.
News
Cogent Biosciences falls -6.8%
Cogent Biosciences (COGT) is down -6.8%, or -$2.16 to $29.48.
Cogent Biosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Bezuclastinib’s first U.S. FDA decision is expected imminently, with launch preparations complete and GIST orders potentially starting within days of approval. Plans include European filings in 2027, further first-line GIST work and additional pipeline assets by year-end 2026.
Cogent Biosciences price target raised to $56 from $55 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cogent Biosciences (COGT) to $56 from $55 and keeps a Buy rating on the shares following the Q3 report. Published first on…
Cogent Biosciences reports Q3 net loss ($111.4M) vs. ($80.9M) last year
Reports Q3 R&D expenses were $75.1M and G&A expenses were $42.1M. “With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST,”…
Cogent Biosciences Earnings release: Q3 2026
Cogent Biosciences released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Cogent Biosciences Quarterly report: Q3 2026
Cogent Biosciences has published its Q3 2026 quarterly earnings report on November 5, 2026.
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application
Cogent Biosciences (COGT) announced that the FDA has accepted its new drug application for bezuclastinib in patients with Advanced Systemic Mastocytosis and assigned a Prescription Drug User Fee Act t...
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
Cogent Biosciences added to Analyst Focus List at JPMorgan
JPMorgan analyst Anupam Rama added Cogent Biosciences (COGT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $62 price target The firm cites…
Cogent Biosciences price target raised to $55 from $52 at Piper Sandler
Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on Cogent Biosciences (COGT) to $55 from $52 with bezuclastinib launch in sight. The firm keeps an Overweight rating…
Cogent Biosciences price target raised to $52 from $45 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Cogent Biosciences (COGT) to $52 from $45 and keeps a Buy rating on the shares. Cogent reported Q2 earnings and…
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30...
Cogent Biosciences Earnings release: Q2 2026
Cogent Biosciences released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Cogent Biosciences Quarterly report: Q2 2026
Cogent Biosciences has published its Q2 2026 quarterly earnings report on August 10, 2026.
Cogent Biosciences submits bezuclastinib NDA to FDA
Cogent Biosciences (COGT) announced it has submitted its new drug application, or NDA, to the FDA for bezuclastinib in Advanced Systemic Mastocytosis. The submission is based on clinical data from…
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated sa...
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –
Cogent Biosciences Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation. All proposals were approved according to management's recommendations, with final results to be filed with the SEC.
Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Bezuclastinib plus sunitinib showed significant efficacy in second-line GIST, with strong physician and patient enthusiasm and a rapid uptake expected upon approval. Regulatory review is expedited, with a PDUFA date of November 30, and the company is well-funded for launch and pipeline development.
Cogent Biosciences announces data from analysis of PEAK Phase 3 trial
Cogent Biosciences (COGT) announced detailed clinical data from the primary analysis of the PEAK Phase 3 trial of bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal ...
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, C...
Cogent Biosciences announces FDA acceptance of bezuclastinib NDA
Cogent Biosciences (COGT) announced that the FDA has accepted its new drug application, or NDA, for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors, or GI...
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 20...